SHP-77 In Vitro Post-translational Modifications Assay

This assay is to provide SHP-77-based In Vitro Post-translational Modifications Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

SHP-77

Human

SHP-77 epithelial cells are derived from a non-encapsulated primary lung tumor from the apical portion of the upper lobe of the left lung of a 54-year-old, White male in 1977. SHP-77 cells can serve as an in vitro target in 51Cr and 111 in release cytotoxicity assays as well as in vivo nude mice assays for evaluating immune reactivity of cells and serum from lung cancer patients. The cells can be used to evaluate the immune status of patients with SCLC who are treated with radiation or chemotherapy.

Lung Cancer

Oncology

In Vitro Post-translational Modifications Assay

Immunoassays and mass spectrometry techniques are considered ideal techniques for the detection of post-translational modification. Both the genetic and epigenetic modifications have contributed to the initiation and progression of cancer.

Gene and Protein Expression Assays

Following transcription, primary transcript RNA is converted into mature RNA by post-transcriptional modifications. Post-transcriptional modification includes three major steps namely the addition of a 5'cap, addition of a 3'polyadenylation tail and RNA splicing. Stability of RNA has been considered as very important for gene expression and proteins at the post-transcriptional level.